Halothane-induced hepatitis: A forgotten issue in developing countries

Hepatitis Monthly

Volumn 11, Issue 1, 2011, Pages 3-6

  Habibollahi, Peiman ^a   Mahboobi, Nastaran ^a   Esmaeili, Sara ^b   Safari, Saeid ^a   Dabbagh, Ali ^c   Alavian, Seyed Moayed ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anesthetics; Halogenated; Halothane; Hepatitis

Indexed keywords

CORTICOSTEROID; DESFLURANE; ENFLURANE; HALOTHANE; METHIONINE; SEVOFLURANE;

ARTICLE; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DRUG METABOLISM; HUMAN; HYPERTRANSAMINASEMIA; INHALATION ANESTHESIA; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; RISK FACTOR; TOXIC HEPATITIS;

EID: 79956227544     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Suckling CW. Some chemical and physical factors in the development of fluothane. Br J Anaesth. 1957;29(10):466-72.
2. Johnstone M. The human cardiovascular response to fluothane anaesthesia. Br J Anaesth. 1956;28(9):392-410.
3. POSTOPERATIVE death after fluothane. Anesthesiology. 1958;19(4):562-3.
4. Brody GL, Sweet RB. Halothane anesthesia as a possible cause of massive hepatic necrosis. Anesthesiology. 1963;24:29-37.
5. Lindenbaum J, Leifer E. Hepatic necrosis associated with halothane anesthesia. N Engl J Med. 1963;268:525-30.
6. Kumar GP, Bhat VJ, Sowdi V. Fulminant hepatic failure following halothane anaesthesia. J Clin Forensic Med. 2005;12(5):271-3.
7. Whalen FX, Bacon DR, Smith HM. Inhaled anesthetics: an historical overview. Best Pract Res Clin Anaesthesiol. 2005;19(3):323-30.
8. van P, Ray BS, Artusio JF, Jr. Methoxyflurane as an anesthetic for neurological surgery. J Neurosurg. 1960;17:477-9.
9. Wasmuth CE, Greig JH, Homi J, Moraca PP, Isil NH, Bitte EM, et al. Methoxyflurane-a new anesthetic agent. A clinical evaluation based on 206 cases. Cleve Clin Q. 1960;27:174-83.
10. Black GW, Clarke RS. Recently introduced anesthetic drugs. Int Anesthesiol Clin. 1971;9(3):171-96.
11. Stevens WC. New Halogenated Anesthetics: Enflurane and Isoflurane. Calif Med. 1972;117(4):47.
12. Eger EI,. Partition coefficients of I-653 in human blood, saline, and olive oil. Anesth Analg. 1987;66(10):971-3.
13. Wallin RF, Regan BM, Napoli MD, Stern IJ. Sevoflurane: a new inhalational anesthetic agent. Anesth Analg. 1975;54(6):758-66.
14. Fazi L, Watcha MF. The economics of newer anaesthetic drugs: should we take the Rolls-Royce or the bicycle today? Paediatr Anaesth. 1999;9(3):181-5.
15. Walton B, Simpson BR, Strunin L, Doniach D, Perrin J, Appleyard AJ. Unexplained hepatitis following halothane. Br Med J. 1976;1(6019):1171-6.
16. Singhal S, Gray T, Guzman G, Verma A, Anand K. Sevoflurane Hepatotoxicity: A Case Report of Sevoflurane Hepatic Necrosis and Review of the Literature. Am J Ther. 2010;17(2):219-22
17. Anderson JS, Rose NR, Martin JL, Eger EI, Njoku DB. Desflurane hepatitis associated with hapten and autoantigen-specific IgG4 antibodies. Anesth Analg. 2007;104(6):1452-3, table of contents.
18. Ihtiyar E, Algin C, Haciolu A, Isiksoy S. Fatal isoflurane hepatotoxicity without re-exposure. Indian J Gastroenterol. 2006;25(1):41-2.
19. Mahboobi N, Esmaili S, Safari S, Habibollahi P, Dabbagh A, Alavian SM. Halothane: how should it be treated in a developing country? EMHJ. 2010; 17(1).
20. Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol. 1988;2(2):385-422.
21. Neuberger J, Williams R. Halothane anaesthesia and liver damage. Br Med J (Clin Res Ed). 1984;289(6452):1136-9.
22. Kenna JG, Jones RM. The organ toxicity of inhaled anesthetics. Anesth Analg. 1995;81(6 Suppl):S51-66.
23. Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddleston AL, Davis M, et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med. 1980;303(2):66-71.
24. Mieli-Vergani G, Vergani D, Tredger JM, Eddleston AL, Davis M, Williams R. Lymphocyte cytotoxicity to halothane altered hepatocytes in patients with severe hepatic necrosis following halothane anaesthesia. J Clin Lab Immunol. 1980;4(1):49-51.
25. Summary of the national Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis. JAMA. 1966;197(10):775-88.
26. Dugan CM, MacDonald AE, Roth RA, Ganey PE. A mouse model of severe halot hane hepatitis based on human risk factors. J Pharmacol Exp Ther. 2010;333(2):364-72.
27. Reichle FM, Conzen PF. Halogenated inhalational anaesthetics. Best Pract Res Clin Anaesthesiol. 2003;17(1):29-46.
28. Carpenter RL, Eger EI, 2nd, Johnson BH, Unadkat JD, Sheiner LB. The extent of metabolism of inhaled anesthetics in humans. Anesthesiology. 1986;65(2):201-5.
29. Gut J. Molecular basis of halothane hepatitis. Arch Toxicol Suppl. 1998;20:3- 17.
30. Spracklin DK, Thummel KE, Kharasch ED. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996;24(9):976-83.
31. Sipes IG, Gandolfi AJ, Pohl LR, Krishna G, Brown BR,. Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. J Pharmacol Exp Ther. 1980;214(3):716-20.
32. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther. 1997;281(1):400-11.
33. Kenna JG, Martin JL, Satoh H, Pohl LR. Factors affecting the expression oftrifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab Dispos. 1990;18(5):788-93.
34. Kenna JG, Neuberger J, Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology. 1988;8(6):1635-41.
35. Satoh H, Fukuda Y, Anderson DK, Ferrans VJ, Gillette JR, Pohl LR. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther. 1985;233(3):857-62.
36. Trudell JR, Ardies CM, Anderson WR. Antibodies raised against trifluoroacetyl-protein adducts bind to N-trifluoroacetyl-phosphatidylethanolamine in hexagonal phase phospholipid micelles. J Pharmacol Exp Ther. 1991;257(2):657-62.
37. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet. 1996;347(9012):1367-71.
38. Christen U, Burgin M, Gut J. Halothane metabolism: Kupffer cells carry and partially process trifluoroacetylated protein adducts. Biochem Biophys Res Commun. 1991;175(1):256-62.
39. Heijink E, De Matteis F, Gibbs AH, Davies A, White IN. Metabolic activation of halothane to neoantigens in C57Bl/10 mice: immunochemical studies. Eur J Pharmacol. 1993;248(1):15-25.
40. Baker MT, Vasquez MT, Chiang CK. Evidence for the stability and cytochrome P450 specificity of the phenobarbital-induced reductive halothane-cytochrome P450 complex formed in rat hepatic microsomes. Biochem Pharmacol. 1991;41(11):1691-9.
41. de Groot H, Noll T. Halothane hepatotoxicity: relation between metabolic activation, hypoxia, covalent binding, lipid peroxidation and liver cell damage. Hepatology. 1983;3(4):601-6.
42. Manno M, Ferrara R, Cazzaro S, Rigotti P, Ancona E. Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothane in vitro. Pharmacol Toxicol. 1992;70(1):13-8.
43. Plummer JL, Beckwith AL, Bastin FN, Adams JF, Cousins MJ, Hall P. Free radical formation in vivo and hepatotoxicity due to anesthesia with halothane. Anesthesiology. 1982;57(3):160-6.
44. Royston D. Free radicals. Formation, function and potential relevance in anaesthesia. Anaesthesia. 1988;43(4):315-20.
45. Christ DD, Kenna JG, Kammerer W, Satoh H, Pohl LR. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology. 1988;69(6):833-8.
46. Carrigan TW, Straughen WJ. A report of hepatic necrosis and death following isoflurane anesthesia. Anesthesiology. 1987;67(4):581-3.
47. Martin JL, Plevak DJ, Flannery KD, Charlton M, Poterucha JJ, Humphreys CE, et al. Hepatotoxicity after desflurane anesthesia. Anesthesiology. 1995;83(5):1125-9.
48. Chase RE, Holaday DA, Fiserova-Bergerova V, Saidman LJ, Mack FE. The biotransformation of ethrane in man. Anesthesiology. 1971;35(3):262-7.
49. Eger EI, 2nd, Smuckler EA, Ferrell LD, Goldsmith CH, Johnson BH. Is enflurane hepatotoxic? Anesth Analg. 1986;65(1):21-30.
50. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med. 1983;98(6):984-92.
51. Holaday DA, Fiserova-Bergerova V, Latto IP, Zumbiel MA. Resistance of isoflurane to biotransformation in man. Anesthesiology. 1975;43(3):325-32.
52. Sutton TS, Koblin DD, Gruenke LD, Weiskopf RB, Rampil IJ, Waskell L, et al. Fluoride metabolites after prolonged exposure of volunteers and patients to desflurane. Anesth Analg. 1991;73(2):180-5.
53. Otedo AE. Halothane induced hepatitis: case report. East Afr Med J. 2004;81(10):538-9.
54. Lo SK, Wendon J, Mieli-Vergani G, Williams R. Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation. Eur J Gastroenterol Hepatol. 1998;10(8):635-9.
55. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755-74.
56. Brown BR, Jr., Gandolfi AJ. Adverse effects of volatile anaesthetics. Br J Anaesth. 1987;59(1):14-23.
57. Trowell J, Peto R, Smith AC. Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium. Lancet. 1975;1(7911):821-4.
58. Wright R, Eade OE, Chisholm M, Hawksley M, Lloyd B, Moles TM, et al. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet. 1975;1(7911):817-20.
59. Holt C, Csete M, Martin P. Hepatotoxicity of anesthetics and other central nervous system drugs. Gastroenterol Clin North Am. 1995;24(4):853-74.
60. Beaune P, Pessayre D, Dansette P, Mansuy D, Manns M. Autoantibodies against cytochromes P450: role in human diseases. Adv Pharmacol. 1994;30:199-245.
61. Windsor JA, Wynne-Jones G. Halothane hepatitis and prompt resolution with methionine therapy: case report. N Z Med J. 1988;101(851):502-3.
62. Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth. 1991;67(1):84-99.
63. Farrell G, Prendergast D, Murray M. Halothane hepatitis. Detection of a constitutional susceptibility factor. N Engl J Med. 1985;313(21):1310-4.
64. Satoh H, Gillette JR, Davies HW, Schulick RD, Pohl LR. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol Pharmacol. 1985;28(5):468-74.
65. You Q, Cheng L, Reilly TP, Wegmann D, Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology. 2006;44(6):1421-31.
66. Voigt MD, Workman B, Lombard C, Kirsch RE. Halothane hepatitis in a South African population--frequency and the influence of gender and ethnicity. S Afr Med J. 1997;87(7):882-5.
67. Bunker JP. Final Report of the National Halothane Study. Anesthesiology. 1968;29(2):231-2.
68. Elliott RH, Strunin L. Hepatotoxicity of volatile anaesthetics. Br J Anaesth. 1993;70(3):339-48.
69. Kharasch ED. Biotransformation of sevoflurane. Anesth Analg. 1995;81(6 Suppl):S27-38.
70. Frink EJ, Jr., Ghantous H, Malan TP, Morgan S, Fernando J, Gandolfi AJ, et al. Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. Anesth Analg. 1992;74(2):231-5.
71. Kanaya N, Nakayama M, Fujita S, Namiki A. Comparison of the effects of sevoflurane, isoflurane and halothane on indocyanine green clearance. Br J Anaesth. 1995;74(2):164-7.
72. Njoku D, Laster MJ, Gong DH, Eger EI, Reed GF, Martin JL. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg. 1997;84(1):173-8.